{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T11:22:59Z","timestamp":1791026579626,"version":"4.1.0"},"reference-count":0,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2014,1,22]]},"DOI":"10.1001\/jama.2013.284531","type":"journal-article","created":{"date-parts":[[2014,1,21]],"date-time":"2014-01-21T23:30:20Z","timestamp":1390347020000},"page":"353","source":"Crossref","is-referenced-by-count":52,"title":["The Accelerated Approval of Oncologic Drugs"],"prefix":"10.1001","volume":"311","author":[{"given":"Vinay","family":"Prasad","sequence":"first","affiliation":[{"name":"Medical Oncology Service, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sham","family":"Mailankody","sequence":"additional","affiliation":[{"name":"Medical Oncology Service, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/1817804","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,12,15]],"date-time":"2016-12-15T18:27:14Z","timestamp":1481826434000},"score":1,"resource":{"primary":{"URL":"http:\/\/jama.jamanetwork.com\/article.aspx?doi=10.1001\/jama.2013.284531"}},"subtitle":["Lessons From Ponatinib"],"short-title":[],"issued":{"date-parts":[[2014,1,22]]},"references-count":0,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,1,22]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2013.284531","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1,22]]}}}